As a tenure-track Assistant Professor at UTEP, I have a strong background in cancer immunology and pharmaceutical sciences. My research focuses on drug discovery and biomarker identification for drug-resistant cancers.

• Top 35 Abstracts, 5th Annual IMMUNO-ONCOLOGY Young Investigators’ Forum - IMMUNO-ONCOLOGY Young Investigators’ Forum (01/01/2019-12/31/2019)
• AACR‐Millennium Scholar-in-Training Award - American Association for Cancer Research (01/01/2013-12/31/2013)
• Trainee Excellence Award - The University of Texas MD Anderson Cancer Center (01/01/2012-12/31/2012)
• AACR-OSI Pharmaceutical Scholar-in-Training Award - American Association for Cancer Research (01/01/2007-12/31/2007)

• Postdoctoral Fellow, Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (2014)
• Ph D in Pharmaceutical Science, University of Arizona (2008)
• MS in Pharmacognosy & Microbial-Biochemical Medicine, Peking Union Medical College (2002)
• B.Pharm. in Microbial-Biochemical Medicine (Micropharmaceutics), Shenyang Pharmaceutical Univer (1997)

• Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth Cancers (Basel) 14(24) (2022), Chandrani Chattopadhyay, Rajat Bhattacharya, Jason Roszik, Fatima Khan, Gabrielle A. Wells, Hugo Villanueva, Yong Qin, Rishav Bhattacharya, Sapna Patel, Elizabeth . Grimm.
• Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury. European Journal of Medicinal Chemistry 230 (2022), Huiqiang Wei , Wenfeng Gou, Jun Gao, Hongxin Ning, Yang Song, Deguan Li, Yong Qin, Wenbin Hou, Yiliang Li.
• Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. Cancers 13 13 (2021), A Ballhausen, E Urias, S K. Gruschkus, M Williams, M S. Glover, Yong Qin, D S. Gombos, S P. Patel.
• iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in oncology 11 (2021), Z Ding, D Ogata, J Roszik, Yong Qin, S H. Kim, M T. Tetzlaff, A J. Lazar, M A. Davies, S Ekmekcioglu, E A. Grimm.
• Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. Journal for immunotherapy of cancer 8 2 (2020), Yong Qin, K Bollin, M P. de Macedo, F Carapeto, K B. Kim, J Roszik, K M. Wani, A Reuben, S T. Reddy, M D. Williams, M T. Tetzlaff, W L. Wang, D S. Gombos, B Esmaeli, A J. Lazar, P Hwu, S P. Patel.
• Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. European journal of medicinal chemistry 181 (2019), H Wei, Y Duan, W Gou, J Cui, H Ning, D Li , Yong Qin, Q Liu, Y Li .
• Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors. Expert opinion on investigational drugs 28 10 (2019), L Chen, Y Duan, H Wei, H Ning, C Bi, Y Zhao, Yong Qin, Y Li .
• Systemic Therapy for Mucosal, Acral and Uveal Melanoma Springer International Publishing (2019), Suthee Rapisuwon, Yong Qin, Jason Roszik, Fernando Carapeto, Sapna Patel, Richard D. Carvajal.
• High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO clinical cancer informatics 2 (2018), M Gianni, Yong Qin, G Wenes, B Bandstra, A P. Conley, V Subbiah, R Leibowitz-Amit, S Ekmekcioglu, E A. Grimm, J Roszik.
• Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. American journal of clinical oncology 41 11 (2018), J Vera-Aguilera, A Y. Bedikian, R L. Bassett, W J. Hwu, K B. Kim, Yong Qin, S Cain, E W. Washington, M A. Davies, S M. Patel, J Homsi, N E. Papadopoulos, P Hwu, S P. Patel.
• Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy. Frontiers in immunology 9 (2018), Y Li , S P. Patel, J Roszik, Yong Qin.

• Immune Profile and Immunosuppresive Mechanism of Uveal Melanoma (2022), Volume El Paso, Texas, Yong Qin.
• Nitrosative Stress-driven S-nitrosylation of Key Molecules in Inflammatory Cancers (2021), Volume Seoul, Korea, Yong Qin.

• Development of novel therapeutics to overcome abemaciclib resistance in various cancers
• SOCS1 AS A CRUCIAL REGULATOR FOR RESISTANT UVEAL MELANOMA RESPONSE TO IMMUNOTHERAPY
• Molecular and immune profiling of Hispanic gastrointestinal cancer disparities
• TARGETING A STRESS-DERIVED IMMUNOSUPPRESSIVE ADENOSINE PATHWAY IN TUMORS RESISTANT TO CHECKPOINT INHIBITORS